Abstract
Omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) supplementation in the cardiovascular field is effective if a certain Omega-3 index (O3I) is achieved or the daily n-3 LCPUFA dose is high enough. Whether this applies to studies on cognition in children and adolescents is unclear. The aims of the current review were to investigate whether: (1) a certain O3I level and (2) a minimum daily n-3 LCPUFA dose are required to improve cognition in 4-25 year olds. Web of Science and PubMed were searched. Inclusion criteria: placebo controlled randomized controlled trial; participants 4-25 years; supplementation with docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA); assessing cognition; in English and >= 10 participants per treatment arm. Thirty-three studies were included, 21 in typically developing participants, 12 in those with a disorder. A positive effect on cognitive measures was more likely in studies with an increase in O3I to >6%. Half of the studies in typically developing children with daily supplementation dose >= 450 mg DHA + EPA showed improved cognition. For children with a disorder no cut-off value was found. In conclusion, daily supplementation of >= 450 mg DHA + EPA per day and an increase in the O3I to >6% makes it more likely to show efficacy on cognition in children and adolescents.
Original language | English |
---|---|
Article number | 3115 |
Number of pages | 25 |
Journal | Nutrients |
Volume | 12 |
Issue number | 10 |
DOIs | |
Publication status | Published - Oct 2020 |
Keywords
- adolescents
- children
- long-chain polyunsaturated fatty acid
- cognition
- Omega-3 Index
- DEFICIT HYPERACTIVITY DISORDER
- ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
- RICH FISH-OIL
- PLACEBO-CONTROLLED INTERVENTION
- DOCOSAHEXAENOIC ACID
- DOUBLE-BLIND
- OMEGA-3-FATTY-ACID SUPPLEMENTATION
- SUSTAINED ATTENTION
- HEALTHY-CHILDREN
- CONTROLLED TRIAL